Harvard's Alzheimer's Guru Joins NeuroSense Ahead of Key Drug Data

CAMBRIDGE, MA – January 08, 2026 – NeuroSense Therapeutics, a late-clinical stage biotechnology company, has significantly bolstered its scientific leadership by appointing world-renowned Alzheimer's disease expert Professor Steven E. Arnold to its Scientific Advisory Board. The move is being widely interpreted as a major vote of confidence in the company's novel therapeutic approach just as it prepares to release critical data for its lead drug candidate, PrimeC, in the first quarter of 2026.

Prof. Arnold, a Professor of Neurology at Harvard Medical School, brings decades of high-level experience in neurodegenerative disease research and biomarker-driven clinical trials. His appointment provides a powerful endorsement for NeuroSense's strategy at a pivotal moment, as the company aims to carve out a niche in the fiercely competitive and challenging landscape of Alzheimer's drug development.

A Titan of Alzheimer's Research Lends His Expertise

Professor Arnold's resume places him at the pinnacle of neuroscience and clinical research. In addition to his professorship at Harvard, he is the Translational Neurology Head and Managing Director of the Interdisciplinary Brain Center at Massachusetts General Hospital. His work there focuses on accelerating therapeutic discovery through innovative, biomarker-intensive clinical trials—a methodology that aligns perfectly with NeuroSense's own data-centric approach.

Before his current roles, Prof. Arnold was a distinguished professor at the University of Pennsylvania, where he directed the esteemed Penn Memory Center. With over 350 scientific publications and board certifications in both neurology and psychiatry, his research has been foundational in understanding the molecular pathology of neurodegenerative diseases and identifying biomarkers for dementia. His expertise is expected to be invaluable as NeuroSense navigates the next stages of clinical development for its Alzheimer's program.

"Prof. Arnold's depth of experience in biomarker-driven clinical development and translational neuroscience aligns closely with how we are advancing our programs," said Alon Ben-Noon, Co-Founder and Chief Executive Officer of NeuroSense. "His perspective will be valuable as we continue to execute across both Alzheimer's disease and ALS."

Prof. Arnold himself noted the scientific rationale behind the company's lead candidate. "PrimeC's multi-target mechanism addresses biological pathways that are highly relevant to Alzheimer's disease," he stated. "I look forward to reviewing the forthcoming clinical and biomarker data and to contributing to the program as it moves forward."

A Multi-Target Strategy in a Crowded Field

Alzheimer's disease, the leading cause of dementia worldwide, affects over 30 million people and remains a condition with no cure and limited effective treatments. For years, the pharmaceutical industry has pursued a "silver bullet" approach, primarily targeting the buildup of amyloid-beta plaques in the brain. This has led to the recent approval of drugs like Eisai and Biogen's Leqembi, which have shown a modest ability to slow cognitive decline but come with significant side effects and require intravenous administration.

NeuroSense is pursuing a different path. The company's strategy is built on the premise that complex diseases like Alzheimer's require a multi-pronged attack. Its lead drug, PrimeC, is a novel oral formulation that combines two FDA-approved drugs, ciprofloxacin and celecoxib. This fixed-dose combination is designed to synergistically target several key disease mechanisms at once: inflammation, iron accumulation, impaired ribonucleic acid ("RNA") regulation, and overall neuron degeneration.

By addressing multiple pathological pathways simultaneously, NeuroSense hopes to achieve a more profound disease-modifying effect than single-target therapies. The convenience of an oral pill also presents a significant potential advantage over the infused antibodies that currently dominate the newly emerging market for Alzheimer's treatments. This unique mechanism is not only being tested in Alzheimer's but also in Amyotrophic Lateral Sclerosis (ALS), based on the hypothesis that these neurodegenerative diseases share common underlying pathologies.

All Eyes on Q1 2026: The High-Stakes Data Readout

The appointment of Prof. Arnold comes at a strategically critical time, with the entire field watching for the top-line results from NeuroSense's proof-of-concept Alzheimer's study, known as RoAD. The company has already announced that the study, which recently concluded, demonstrated a favorable safety and tolerability profile for PrimeC, with no new safety signals detected.

More promisingly, early data from patient-derived neurons, analyzed in collaboration with NeuroKaire, showed that PrimeC enhanced neuroplasticity and improved brain-cell connectivity—key factors related to memory and cognitive function. Furthermore, biomarker data from plasma samples in a separate ALS trial showed that PrimeC significantly reduced levels of several microRNAs known to be involved in Alzheimer's pathology, suggesting a direct impact on the disease's biological processes.

However, the comprehensive clinical and biomarker outcomes expected in the coming weeks will be the true test. Investors and scientists will be looking for two key things: first, any positive trends in cognitive or functional assessments among patients; and second, robust changes in biological markers that confirm PrimeC is hitting its intended targets in the human brain. Positive data on both fronts would provide strong validation for the drug's multi-target mechanism and pave the way for larger, pivotal trials.

The Corporate Strategy: Bolstering Confidence Amid Financial Pressures

For a clinical-stage biotech like NeuroSense (NASDAQ: NRSN), perception and scientific validation are as crucial as capital. Bringing a luminary like Prof. Arnold on board is a clear strategic move to bolster investor confidence and underscore the scientific rigor of its Alzheimer's program ahead of the high-stakes data release. The company's stock has been highly reactive to clinical news, and this appointment provides a stabilizing narrative of expert validation.

With a reported cash position of $3.4 million at the end of 2024 and ongoing R&D expenses, the company is operating in a capital-intensive environment where positive clinical results are essential for securing future funding and partnerships. The upcoming data from the RoAD study is therefore more than a scientific milestone; it is a critical inflection point that could determine the trajectory of the company's Alzheimer's program and its financial future.

As the first quarter of 2026 approaches, the addition of Professor Arnold to its advisory board ensures NeuroSense has world-class expertise to interpret the forthcoming results and strategically plan the path forward. The entire Alzheimer's community, from patients and physicians to investors, now waits to see if this multi-target approach, backed by top-tier scientific guidance, can deliver a meaningful breakthrough in the relentless fight against neurodegeneration.